Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAATEO
2024-513766-20-00Phase 2Authorised
- Sponsor
- Oxcia
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of karonudib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and 3 more (2 arms), sponsored by Oxcia. Primary endpoints: Safety and tolerability of Karonudib monotherapy (Part I) and Safety and tolerability of Karonudib in combination (Part II). Planned start Apr 2024; status: authorised.
02
Drugs
karonudib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-513766-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513766-20-00.